

UBS (Lux) Equity Fund - Greater China (USD)

Important information:


- The Fund primarily invests in equities and other equity shares of companies domiciled in the People's Republic of China or Taiwan as well as in other companies domiciled in East Asia which have close economic links with the People's Republic of China or Taiwan.
- The Fund invests in certain Asian markets that are classified as 'emerging markets'. Investment in emerging markets suffer from certain risks such as increased risk of expropriation, nationalization and social, political and economic insecurity; acquisition of counterfeit securities by the Fund; low liquidity and high price (and performance) volatility; substantial currency fluctuations; settlement and custody risks; restrictions on the buying of securities by foreign investors; accounting, auditing and reporting standards, methods, practices and disclosures required by companies in emerging markets being different from those in developed markets.
- The Fund may be subject to concentration risk. In a market downturn such portfolios can suffer more substantial losses than diversified portfolios, i.e. portfolios where investments are spread over different assets, market sectors and/or geographical regions.
- The Fund may invest in financial derivative instruments to gain or reduce exposure to markets and currencies as well as to manage risk. The use of derivatives may involve additional risk, e.g. general market risk, management risk, credit, liquidity risk. Under extreme market conditions and circumstances, the use of derivative financial instruments may potentially result in total loss.
- Investors should not invest in the Fund solely based on this document and should read the relevant offering document.



Investment objective & strategy

- Actively managed equity fund investing within the Greater China region which includes China, Hong Kong and Taiwan
- Diversified across sectors offering broad coverage of Greater China markets.

Performance since 2002 (share class P-acc; basis USD, net of fees)¹



Name of fund	UBS (Lux) Equity Fund - Greater China
Currency of fund	USD
Currency of share class	USD
Fund type	Open-end
Accounting year ends	30 November
Issue/redemption	Daily
Total fund assets (USD m)	913.16
Front End Load	P-acc: up to 5% of subscription amount
Ref Index	UBS Greater China Index

in %	Year-to-date	1 year	3 years	5 years	since launch *
Fund (USD) P-acc	-25.48	-25.93	-16.25	-0.70	300.55
Ref Index ²	-22.15	-22.58	-3.62	-5.00	190.76
in %	2017	2018	2019	2020	2021
Fund (USD) P-acc	54.34	-13.72	41.27	33.31	-20.42
Ref Index ²	-	-16.14	23.48	26.34	-8.51

¹ Fund performance is calculated on NAV to NAV basis in denominated currency of the respective share class with dividends re-invested. These figures refer to the past. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Source for all data and charts (if not indicated otherwise): UBS Asset Management

² Ref Index in currency of share class (without costs)

*(USD) P-acc share class launch date: 31 January 1997

Share class details

	P-acc
Net asset value (USD, 30.11.2022)	400.55
Last 12 Months(USD) – high	563.55
– low	307.16
Management fee % p.a.	1.87
Securities number	547 581
ISIN	LU0072913022
Bloomberg	UBSCHDI LX
Launch Date	31.01.1997
Distribution	Reinvestment

Fund statistics

	3 years	5 years
Beta	1.09	1.08
Volatility ¹		
– Fund	27.26%	24.86%
– Ref Index	24.09%	21.87%
Sharpe ratio	-0.24	-0.06
Risk free rate	0.79%	1.34%

¹ Annualised standard deviation

Market exposure (%)

	Fund
China	82.5
Taiwan	9.2
Cash	5.8
Hong Kong	2.4

10 largest equity positions (%)

	Fund
TAIWAN SEMICONDUCTOR TWD10	9.23
TENCENT HOLDINGS LTD	8.58
KWEICHOW MOUTAI CO LTD A	8.34
NETEASE INC	6.69
CSPC PHARMACEUTICAL GROUP LT	5.68
PING AN INSURANCE 'H' CNY1	4.91
CHINA MERCHANTS BANK CNY1	4.49
ANHUI GUJING DISTL 'B' CNY1	4.25
ALIBABA GROUP HOLDING LTD	3.97
PING AN BANK CO LTD A	3.46
Total	59.60

This information should not be considered as recommendation to buy and sell any particular security.

Investment involves risks, and past performance figures shown are not indicative of future performance. The value of the funds and income from them can go up as well as down and consequently you may not get back the amount originally invested. Investors please refer to the offering document for further details including the risk factors.

The investment returns of some of our range of funds are denominated in currency other than USD/HKD. US/HK Dollar-based investors are therefore exposed to fluctuations in the US/HK dollar/ foreign currency exchange rate.

Units of UBS funds mentioned in this publication may not be offered, sold or delivered in the USA.

The document has not been reviewed by the Securities and Futures Commission in Hong Kong. The document is issued by UBS Asset Management (Hong Kong) Limited.

A number of comments in this document are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS Asset Management’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

You are advised to exercise caution in relation to this document. The information in this document does not constitute advice and does not take into consideration your investment objectives, legal, financial or tax situation or particular needs in any other respect. Investors should be aware that past performance of investment is not necessarily indicative of future performance. Potential for profit is accompanied by possibility of loss. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. Source for all data and charts (if not indicated otherwise): UBS Asset Management.

© UBS 2022. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.